Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C3H8N2S.BrH |
| Molecular Weight | 185.086 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Br.CCSC(N)=N
InChI
InChIKey=SWXXKWPYNMZFTE-UHFFFAOYSA-N
InChI=1S/C3H8N2S.BrH/c1-2-6-3(4)5;/h2H2,1H3,(H3,4,5);1H
| Molecular Formula | BrH |
| Molecular Weight | 80.912 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C3H8N2S |
| Molecular Weight | 104.174 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
TrioxBio's API, S-ethylisothiouronium diethylphosphate, MTR-104 (MTR- 105), is a nitric oxide synthase (NOS) inhibitor which blocks the production of nitric oxide, preventing the dilation of blood vessels and the other detrimental effects caused by excessive NOS activity. MTR-105, a
fast-acting synthetic NOS inhibitor with rapid onset of action when administered parenterally, has
been effective in alleviating hypotension experimentally
and in several observational studies while reducing NO
production. MTR-105 is registered and approved for clinical use in the Republic of Moldova where data have been
collected from 434 patients exposed to the drug in pre- and postapproval clinical investigations.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| L-arginine increases dopamine transporter activity in rat striatum via a nitric oxide synthase-dependent mechanism. | 2004 Dec 1 |
|
| Contribution of nitric oxide produced by inducible nitric oxide synthase to vascular responses of mesenteric arterioles in streptozotocin-diabetic rats. | 2004 Jan |
|
| Calcium/calmodulin-dependent nitric oxide synthase activity in the CNS of Aplysia californica: biochemical characterization and link to cGMP pathways. | 2005 Apr |
|
| [The estimation of the nitric oxide role in the aggravation of combined radiation-thermal injuries]. | 2005 May-Jun |
|
| Nitric Oxide does not mediate Atrogin-1/MAFbx upregulation by inflammatory mediators. | 2008 |
|
| Brain neuronal/inducible nitric oxide synthases and cyclooxygenase-1 are involved in the bombesin-induced activation of central adrenomedullary outflow in rats. | 2008 Aug 20 |
|
| Nitrosylation of ISG15 prevents the disulfide bond-mediated dimerization of ISG15 and contributes to effective ISGylation. | 2008 Sep 5 |
|
| Short-term regulation of tumor necrosis factor-alpha-induced lipolysis in 3T3-L1 adipocytes is mediated through the inducible nitric oxide synthase/nitric oxide-dependent pathway. | 2009 Nov |
|
| Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa. | 2012 Mar 8 |
|
| Role of ion channels in sepsis-induced atrial tachyarrhythmias in guinea pigs. | 2012 May |
|
| Depletion of circulating blood NOS3 increases severity of myocardial infarction and left ventricular dysfunction. | 2014 Jan |
Patents
Sample Use Guides
Thirty-six patients with an ejection fraction >50% undergoing open-heart surgery were randomly assigned to either 50 ug kg(-1) min(-1) MTR-105 (M50, n = 12), 10 ug kg(-1) min(-1) MTR-105 (M10, n = 12) or buffered phosphate solution (placebo control, n = 12). Intravenous MTR-105 was administered continuously starting at aortic cross-clamp removal and ending 6 h later. MTR-105 doses were associated with an immediate increase in systemic blood pressure (16%) and systemic vascular resistance and a decrease in cardiac index.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:25:49 GMT 2023
by
admin
on
Sat Dec 16 12:25:49 GMT 2023
|
| Record UNII |
T9389OA11M
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
T9389OA11M
Created by
admin on Sat Dec 16 12:25:49 GMT 2023 , Edited by admin on Sat Dec 16 12:25:49 GMT 2023
|
PRIMARY | |||
|
DTXSID90147913
Created by
admin on Sat Dec 16 12:25:49 GMT 2023 , Edited by admin on Sat Dec 16 12:25:49 GMT 2023
|
PRIMARY | |||
|
27208
Created by
admin on Sat Dec 16 12:25:49 GMT 2023 , Edited by admin on Sat Dec 16 12:25:49 GMT 2023
|
PRIMARY | |||
|
1071-37-0
Created by
admin on Sat Dec 16 12:25:49 GMT 2023 , Edited by admin on Sat Dec 16 12:25:49 GMT 2023
|
PRIMARY | |||
|
200213
Created by
admin on Sat Dec 16 12:25:49 GMT 2023 , Edited by admin on Sat Dec 16 12:25:49 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |